Merck Animal Health Announces the Availability of ARMATREX™ Spray-On Antimicrobial Solution in Partnership with Good Salt™ Life, LLC   

Novel product addresses environmental pathogen load in animal health facilities to enhance biosecurity measures

RAHWAY, N.J., May 13, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the commercial availability of ARMATREX™ (silane quaternary ammonium salt), an EPA-registered, spray-on antimicrobial solution, as part of a partnership agreement with Good Salt™ Life, LLC, the product manufacturer. Merck Animal Health will market and sell the product in the United States.

          ARMATREX is an odorless, colorless and non-toxic solution. It creates an invisible and durable barrier to inhibit the growth of bacteria, fungi, mold and algae. The barrier provides up to 90 days of protection and antimicrobial activity and can enhance biosecurity when used in conjunction with cleaning and disinfecting protocols.

          “The importance of biosecurity and protecting animals and property from disease spread is a top concern for consumers and producers alike,” said Justin Welsh, D.V.M., executive director of livestock technical services at Merck Animal Health. “Directly aligned with our strategy of prevention, we are excited to partner with Good Salt Life, LLC to provide this innovative product because biosecurity and pathogen control are essential parts of the food supply chain.”

           “Keeping animals healthy starts with maintaining clean environments. That’s really what this partnership is about,” said Adrian Fulle, President and CEO of Good Salt Life, LLC. “ARMATREX gives producers and other animal health stakeholders an easy-to-use tool that works long after it’s applied. We’re excited to work with Merck Animal Health to provide this technology to market and help improve biosecurity across animal health facilities.”

           “ARMATREX can be used in a variety of animal health settings to meet various biosecurity needs,” added Welsh.

          The ready-to-use formulation does not require mixing or measuring. ARMATREX can be applied with induction-charged technology to provide uniform coverage of treated surfaces, decreasing product waste. It does not cause microbial adaptation, resistance or mutation.

          ARMATREX is available in 1-gallon, 5-gallon, or 55-gallon presentations from Merck Animal Health or its distributors. In addition to ARMATREX™, Good Salt Life, LLC offers advanced chemical delivery systems for antimicrobial solutions on surfaces. By leveraging innovative technology, these systems help ensure efficient and thorough application, reducing product waste while enhancing biosecurity and pathogen control in animal health facilities.

          To learn more, visit https://www.merck-animal-health-usa.com/channel-content/species/others/armatrex.

Product Label

Merck Animal Health, in partnership with Good Salt Life, LLC, announces the availability of ARMATREX™, an EPA-registered, spray-on antimicrobial solution to reduce environmental pathogen load in animal health facilities and enhance biosecurity measures. ARMATREX is available in 1-gallon, 5-gallon, or 55-gallon presentations from Merck Animal Health or its distributors.

About Merck Animal Health

          At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals^®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram.

About Good Salt Life, LLC

          Good Salt Life, LLC is dedicated to promoting vitality through eco-friendly, nature-derived products that support healthier living environments. With a focus on innovation and sustainability, the company offers safe and effective solutions for home, pet, personal care, and animal health. Through strategic partnerships, including collaborations in the B2B animal health sector, Good Salt Life, LLC continues to drive advancements that benefit both people and animals. For more information, visit www.goodsaltlife.com.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

          This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

          Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

          The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).